Late Incomplete Stent Apposition Evaluation II: Comparison Between Polimer-based and No-polimer Stent System. IVUS Based Study (LISAII)

Late Incomplete Stent Apposition Evaluation II: Vascular Effects Evaluation After Polimer and No-polimer Based Coronary Artery Drug Eluting Stent Ilmplantation. An IVUS Based Study

Vascular effects evaluation after non-polimeric and polimeric paclitaxel stent implantation.In particular the investigators will use Taxus )as a polimeric stent)and Axxion (as a non-polimeirc)stent system. The investigators will look at late stent malapposition by means of intracoronary ultrasound imaging technique (IVUS) at baseline and 9 months follow-up. The investigators sought to compare the two stent types with the same drug to verify the polimer role. The polimer itself seems to provoke inflammation and hypersensibility if the arterial wall and it seems to be the base of a process of positive remodeling found at drug eluting stent implantation site.

This positive remodeling is the mechanism producing late stent malapposition which on its turn can determine stent thrombosis, as demonstrated by pathological studies. At the same time the investigators will study the incidence of clinical events like myocardial infarction, stent thrombosis, TLR and death along with the incidence of angiographic restenosis at 2 years follow up.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

320

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Barcelona, Spain, 08025
        • Recruiting
        • Hospital de la Santa Creu y Sant Pau
        • Principal Investigator:
          • Manel Sabate, MD, PhD
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Victoria Martin Yuste, MD
        • Sub-Investigator:
          • Clarissa Cola, MD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with coronary artery stenosis in one, two or three vessels, and with objective evidence of isquemia.
  • The stenosis must allow IVUS analisis, must be treatable with angioplasty with stent
  • Target Vessel diameter must be between 2.25- 4 mm with QCA.
  • Patients must sign informed consent
  • Patients and their physician must accept the angiographic follow-up

Exclusion Criteria:

  • 18 years old patients
  • SCA within the last 72 hours, or patients with CK twice over the upper normal limit
  • Pregnancy
  • Target vessel diameter < 2.25 or > 4 mm by QCA
  • Previous brakitherapy or DES in the target lesion
  • Restenotic lesion
  • -Allergy to aspirin, clopidogrel or ticlopidin
  • Patients enrolled in other studies or trials
  • By-pass graft lesions
  • Real bifurcationa lesions
  • Severe Renal insufficiency (creatinin clearance < 30 ml/min).
  • Severe Liver failure(GOT y GPT > 3 times the upper normal limit)
  • Life expectancy < 1 year because of other pathologies

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Polimeric-PES
Arm receiving polimeric stent (Taxus)
Coronary artery stent implantation
Active Comparator: Non-Polimeric PES
Arm receiving non-polimeric PES (axxion)
Coronary artery stent implantation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Intra coronary ultrasound analysis to verify stent malapposition at follow-up
Time Frame: 9 months
9 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Clinical events (myocardial infarction, TLR,at 1, 9, 12, 24 months follow-up:; Incidence of restenosis with QCA at 9 months follow-up Intimal hiperplasia measured by IVUS at 9 months follow-up; Stent Thrombosis.
Time Frame: 9 months and 2 years
9 months and 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Manel Sabate, MD, PhD, Hospital de la Santa Creu Y Sant Pau, Unidad de Hemodinamica

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2007

Study Registration Dates

First Submitted

December 28, 2010

First Submitted That Met QC Criteria

June 16, 2011

First Posted (Estimate)

June 17, 2011

Study Record Updates

Last Update Posted (Estimate)

June 17, 2011

Last Update Submitted That Met QC Criteria

June 16, 2011

Last Verified

February 1, 2007

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on Percutaneous transluminal Coronary Angioplasty

3
Subscribe